AstraZeneca
Cambridge, UK
AstraZeneca is a pharmaceutical company engaged in multi-year AI-powered drug discovery collaborations to identify validated targets in various disease areas.
How We Help
Problem Statement
To address unmet medical needs by pioneering the research, development, manufacturing, and commercialization of innovative prescription medicines for a wide range of debilitating and life-threatening diseases.
Core Technology
AI-powered drug discovery
Key Differentiators
Substantial investment in R&D and a robust product pipeline, a differentiation strategy particularly in oncology and rare diseases with advanced and targeted therapies, strategic partnerships (e.g., Daiichi Sankyo), global reach, strong brand recognition, extensive intellectual property portfolio, commitment to sustainability, and integration of digital transformation initiatives.
Clinical Focus
Precision Medicine
Target Customers
Healthcare providers, hospitals, pharmacies, and patients worldwide.
Product Stage
GA/Mature
Company Info
- Business Model
- Pharmaceutical R&D, manufacturing, and commercialization of prescription medicines, primarily generating revenue through product sales, licensing agreements, royalties, and milestone payments from partnerships.
- Founded
- 1999
- Website
- www.astrazeneca.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Multiple FDA and EU approvals for key drugs: - IMFINZI® (durvalumab): US/EU approved for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers (Nov 2025/Mar 2026), resectable early-stage NSCLC (Aug 2024), perioperative regimen for muscle-invasive bladder cancer, and first-line treatment for primary advanced or recurrent endometrial cancer. Matterhorn Phase III trial showed significant overall survival improvement; POTOMAC Phase III met disease-free survival endpoint. - DATROWAY® (datopotamab deruxtecan-dlnk): US approval for EGFR-mutated NSCLC (June 2025), initial indication for HR-positive, HER2-negative breast cancer (2025). Granted Priority Review for unresectable or metastatic TNBC (FDA action date June 2, 2026) based on TROPION-Breast02 trial. - CALQUENCE (acalabrutinib): FDA approved in combination with venetoclax as first all-oral, fixed-duration regimen in US for CLL/SLL (Feb 2026) based on Phase III AMPLIFY trial. Also approved in UK, EU, and Canada. - ENHERTU® (trastuzumab deruxtecan): Granted US Priority Review as post-neoadjuvant treatment for HER2-positive early breast cancer (Mar 2026). - Elecoglipron (AZD5004): Positive top-line results in Phase IIb VISTA (obesity) and SOLSTICE (type 2 diabetes) studies, moving to Phase III development. - BREZTRI: Positive and clinically meaningful results from Phase III KALOS and LOGOS trials for uncontrolled asthma published (Feb 2026). - BAXDROSTAT: Showed efficacy in the BaxAsia trial and filed in the US for hard-to-treat hypertension.
IP Protection
Extensive intellectual property portfolio.
MedStartr Index Score
?What do you think of AstraZeneca?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.